Drug Trial Radar · NCT04999761
AB122 Platform Study
Last checked: Nov 19, 2026Latest source record: Aug 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
917
Planned (sponsor's estimate)
Start
Jun 1, 2021
Primary completion
Jun 2027
Study completion Jun 2027
Sponsor
- Lead sponsor
- Taiho Pharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Aug 11, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a phase 1, non-randomized open-label, multicenter platform study designed to evaluate the tolerability and safety of AB122 in patients with malignancies specified in each cohort.
Conditions
- Advanced or Metastatic Solid Tumor
- Pancreatic Ductal Adenocarcinoma
- Colorectal Cancer
- Non-small Cell Lung Cancer
- Gastric Cancer
- Alveolar Soft Part Sarcoma
- Esophageal Cancer
- Head and Neck Cancer
- Biliary Tract Cancer
Interventions
AB122Drug
AB122 will be administered with 360 mg/body given by infusion over 60 minutes Q3W.
AB122Drug
AB122 will be administered with 240 mg/body given by infusion over 60 minutes Q2W.
TAS-116Drug
TAS-116 will be administered orally in 5-day on and 2-day off schedule on an empty stomach at least 1 hour before or 2 hour after eating.
TAS-120Drug
TAS-120 will be administered orally once daily (QD) on an empty stomach at least 1 hour before or 2 hours after eating.
TAS-115Drug
TAS-115 will be administered orally in 5-day on and 2-day off schedule on an empty stomach at least 1 hour before or 2 hours after eating.
TAS-102Drug
TAS-102 will be administered orally twice daily at a dose calculated based on body surface area (BSA) within 1 hour after morning and evening meals for 5 days, a week with 2 days rest for 2 weeks, followed by a 14-day rest, repeated every 4 weeks.
RamucirumabDrug
Ramucirumab will be administered by infusion at a dose calculated using the body weight over approximately 60 minutes every 2 weeks.
TAS-102Drug
TAS-102 will be administered orally twice daily at a dose calculated based on BSA within 1 hour after morning and evening meals for 5 days, a week with 2 days rest for 2 weeks, followed by a 14-day rest, repeated every 4 weeks.
BevacizumabDrug
Bevacizumab will be administered by infusion at a dose calculated using the body weight over approximately 90 minutes every 2 weeks.
FluorouracilDrug
Fluorouracil will be administered with 800 mg/m2/day given by continuous intravenous infusion from Day 1 to Day 5.
CisplatinDrug
Cisplatin will be administered with 80 mg/m2 given by infusion every 3 weeks.
AB154Drug
AB154 will be administered with 1200 mg/body given by infusion over 60 minutes every 3 weeks.
FluorouracilDrug
Fluorouracil will be administered with 1000 mg/m2/day given by continuous intravenous infusion from Day 1 to Day 4.
CarboplatinDrug
Carboplatin will be administered with AUC 5 given by infusion every 3 weeks.
CisplatinDrug
Cisplatin will be administered with 100 mg/m2 given by infusion every 3 weeks.
CarboplatinDrug
Carboplatin will be administered with AUC 6 given by infusion every 3 weeks.
nab-PaclitaxelDrug
Nab-Paclitaxel will be administered with 100 mg/m2 given by infusion on Day 1, Day 8 and Day 15.
CisplatinDrug
Cisplatin will be administered with 25 mg/m2 given by infusion on Day 1 and Day 8.
GemcitabineDrug
Gemcitabine will be administered with 1000 mg/m2 given by infusion on Day 1 and Day 8.
nab-PaclitaxelDrug
Nab-Paclitaxel will be administered with 125 mg/m2 given by infusion on Day 1, Day 8 and Day 15.
GemcitabineDrug
Gemcitabine will be administered with 1000 mg/m2 given by infusion on Day 1, Day 8 and Day 15.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase 1a (All cohorts except Cohort D-4, D-5 and D-9) : Percentage of participants who experience a Dose Limiting Toxicity (DLT)Time frame: From first study treatment administration through Day 21 (Q3W arm) or Day 28 (Q2W arm)
- Phase 1a (Cohort D-4, D-5 and D-9) : Percentage of adverse events and treatment-related adverse events.Time frame: From first study treatment administration through Day 21 (Q3W arm) or Day 28 (Q2W arm)
- Phase 1b (Cohort B-n, D-n and E-n) : Objective Response Rate (ORR)Time frame: Through completion of treatment (estimated up to be 11 months)
- Phase 1b (Cohort C-n): The 6-month PFS proportion by RECIST v1.1Time frame: Through completion of treatment (estimated up to be 11 months)
Locations
9 sites in 1 country. Site status is shown where the registry gives one.
A site selected by Taiho Pharmaceutical Co., Ltd.
Aichi, Japan · Recruiting
A site selected by Taiho Pharmaceutical Co., Ltd.
Chiba, Japan · Recruiting
A site selected by Taiho Pharmaceutical Co., Ltd.
Ehime, Japan · Recruiting
A site selected by Taiho Pharmaceutical Co., Ltd.
Hokkaido, Japan · Recruiting
A site selected by Taiho Pharmaceutical Co., Ltd.
Kanagawa, Japan · Recruiting
A site selected by Taiho Pharmaceutical Co., Ltd.
Osaka, Japan · Recruiting
A site selected by Taiho Pharmaceutical Co., Ltd.
Shizuoka, Japan · Recruiting
A site selected by Taiho Pharmaceutical Co., Ltd.
Tokyo, Japan · Recruiting
A site selected by Taiho Pharmaceutical Co., Ltd.
Wakayama, Japan · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.